---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268875"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:42:00.269646+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AlloVir Q3 net loss $44.3M ($0.39/sh); cash $213.3M funds trials to H2 2024 data

## Summary
- Net loss $44.3M vs $42.1M in Q3 2022; diluted EPS loss $0.39 vs $0.50.
- Cash, equivalents and short-term investments $213.3M at Sep 30, down from $233.8M at Dec 31, 2022.
- R&D expense $34.2M, up from $30.0M YoY, driven by posoleucel trial costs.
- Three Phase 3 posoleucel trials enrolling; topline data expected in H2 2024 for all three.
- FY 2023 operating expense guidance $150M-$170M, excluding non-cash items.

## SEC filing metadata
- accession: 0001193125-23-268875
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/0001193125-23-268875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/d559627d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268875
- JSON: https://secwatch.observer/filing/0001193125-23-268875.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268875.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income net loss was $44.3 million or $0.39 per share, EPS $0.39 per share.
  - Period: the quarter ended September 30, 2023
  - Net income: net loss was $44.3 million or $0.39 per share
  - EPS: $0.39 per share
  - Result: reported results
  source text: On November 2, 2023, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/0001193125-23-268875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.